Tech Company Financing Transactions
Seraphina Therapeutics Funding Round
On 5/21/2020, Seraphina Therapeutics landed $5.5 million in Series A funding from Domain Associates and private investors.
Transaction Overview
Company Name
Announced On
5/21/2020
Transaction Type
Venture Equity
Amount
$5,500,000
Round
Series A
Investors
Domain Associates (Lead Investor)
Proceeds Purpose
It plans to use this fundraise to advance C15:0 as dietary supplements and food fortifiers to address C15:0 deficiencies and to strengthen cells, enhance mitochondrial function and nutritionally guard against age-related breakdown.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2850 Womble Rd. 100-600
San Diego, CA 92106
USA
San Diego, CA 92106
USA
Phone
Undisclosed
Email Address
Overview
Seraphina Therapeutics is a consortium of scientists, doctors and innovators that uses metabolomics to challenge long held approaches to nutrition, enabling the creation of natural and safe health products designed to support quality of life. We aim to advance products, starting with key fatty acids, that replenish micronutrients and metabolites our bodies already have but need more of as we age.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Kim Kamdar
Chief Executive Officer
Stephanie Venn-Watson
Chief Operating Officer
Eric Venn-Watson
Co-Founder
Nicholas Schork
Browse more venture capital transactions:
Prev: 5/21/2020: Aqua Security venture capital transaction
Next: 5/21/2020: Big Sky Health venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs